Literature DB >> 1714529

High prevalence of benign prostatic hypertrophy in the community.

W M Garraway1, G N Collins, R J Lee.   

Abstract

There is a strong suspicion among urologists that the prevalence of benign prostatic hyperplasia is higher than has been reported in clinical retrospective and necropsy studies. To find out the prevalence in one community all men aged 40-79 years registered with a group general practice were invited to complete a urinary symptom questionnaire and to undergo uroflowmetry. 705 men (77% of those eligible) participated. 214 men (84% of those invited) with signs and symptoms of prostatic dysfunction subsequently underwent transrectal ultrasonography (TRUS) for assessment of the volume (and by inference weight) of their prostates. The prevalence rate of benign prostatic hypertrophy (BPH), defined as enlargement of the prostate gland of equivalent weight greater than 20 g in the presence of symptoms of urinary dysfunction and/or a urinary peak flow rate less than 15 ml/s and without evidence of malignancy, was 253 (95% CI 221-285) per 1000 men in the community, rising from 138 per 1000 men aged 40-49 years to 430 per 1000 men aged 60-69 years. Thus apparently well men have a much higher frequency of BPH than was previously thought to be the case.

Entities:  

Mesh:

Year:  1991        PMID: 1714529     DOI: 10.1016/0140-6736(91)90543-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  128 in total

1.  The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.

Authors:  P O Gisleskog; D Hermann; M Hammarlund-Udenaes; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 2.  Review of current and future approaches to the management of benign prostatic hyperplasia.

Authors:  J C Gingell
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

Review 3.  Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.

Authors:  Donald MacDonald; Thomas A McNicholas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  BPH: unmet needs in managing LUTS--a European perspective.

Authors:  Cosimo De Nunzio; Andrea Tubaro
Journal:  Nat Rev Urol       Date:  2011-11-29       Impact factor: 14.432

Review 5.  Benign prostatic hyperplasia.

Authors:  A Melville; J Donovon; T Sheldon; T Peters
Journal:  Qual Health Care       Date:  1996-06

Review 6.  The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function.

Authors:  Gillian L Stearns; Jaspreet S Sandhu
Journal:  Curr Urol Rep       Date:  2015-11       Impact factor: 3.092

7.  Lower urinary tract symptoms in men.

Authors:  Christopher R Chapple; Anand K Patel
Journal:  BMJ       Date:  2007-01-06

8.  Is nighttime voiding normal or anomalous?

Authors:  M O'leary; M B Chancellor
Journal:  Rev Urol       Date:  2001

9.  Shared care between general practitioners and urologists in the management of benign prostatic hyperplasia: a survey of attitudes among clinicians.

Authors:  R S Kirby; G Chisholm; C Chapple; C Hudd; M Swallow; D Shore
Journal:  J R Soc Med       Date:  1995-05       Impact factor: 5.344

10.  Development of a quality of life scale specific for patients with benign prostatic hyperplasia.

Authors:  Kamil Cam; Talha Muezzinoglu; Omer Aydemir; Recep Buyukalpelli; Gokhan Toktas; Hakan Gemalmaz
Journal:  Int Urol Nephrol       Date:  2013-02-19       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.